The research company Peptonic Medical, which is proceeding with a rights issue, states that the company is debt-free after completing its reorganization, and the board assesses that the new share issue, the warrants and the expected sales from the company's portfolio of intimate care products will cover the company's liquidity needs for at least the next 12 months."The company's financing is supported by a strong financial cornerstone investor and several committed stakeholders. During the reorganization, the company has had clear support from the shareholders. In addition, there are underwriting guarantees that can secure capital if needed. Confidence in, and willingness to continue investing in, the company's future remains strong. Operations have been streamlined significantly over the past 18 months, and we are now concluding the reorganization process as a debt-free company. This marks a clear new start," says Chair Anders Blom in a comment. Peptonic Medical further states that operationally it aims to increase sales and expand into new markets such as Norway, the United Kingdom and the USA. Market share is to increase in Sweden.The company has also entered into a distribution agreement with Joylux regarding markets such as the USA, Canada and Mexico. Launch is expected in the second quarter and production is underway. Furthermore, margins are improving through optimization of inventory management, logistics, pricing and production processes. The sales model has also shifted from a primary focus on white-label solutions to sales under its own brands.